![Andrew von Eschenbach](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Andrew von Eschenbach
Directeur/Membre du Conseil chez
BAUSCH + LOMB CORPORATION
Fortune : 1 M $ au 30/06/2026
Profil
Dr. Andrew C.
von Eschenbach, MD, is an Independent Director at Bausch + Lomb Corp., an Independent Director at Viamet Pharmaceuticals Corp.
and a President at Samaritan Health Initiatives, Inc. He is on the Board of Directors at Bausch + Lomb Corp., Wavebreak Therapeutics Ltd., Reagan-udall Foundation, Viamet Pharmaceuticals Corp., Viamet Pharmaceuticals, Inc., Focused Ultrasound Foundation, Banyan Biomarkers, Inc., Innocrin Pharmaceuticals Holdings LLC, Innocrin Pharmaceuticals, Inc., National Comprehensive Cancer Network Foundation and Bausch & Lomb, Inc. Dr. von Eschenbach was previously employed as an Independent Director by TriSalus Life Sciences, Inc., an Independent Director by Celularity, Inc., an Independent Director by Radius Health, Inc., an Independent Director by Bausch Health Cos., Inc., an Independent Director by Asterias Biotherapeutics, Inc., a Council Member by Eli Lilly & Co., an Independent Director by BioTime, Inc., an Independent Non-Executive Director by Elan Corp.
Plc, a Commissioner by US Food & Drug Administration, a Director-National Cancer Institute by National Institutes of Health, a Director-FDA Project by Manhattan Institute For Policy Research, Inc., a Principal by The University of Texas at Austin, and a Director-Prostate Cancer Research by The University of Texas M.D.
Anderson Cancer Center.
He also served on the board at Celularity, Inc. (United States), Insight Molecular Diagnostics, Inc., National Comprehensive Cancer Network, Inc., National Cancer Institute, Cypher Genomics, Inc. and HistoSonics, Inc. He received his undergraduate degree from St. Joseph's University and a doctorate degree from Georgetown University School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 26/05/2026 | 86 656 ( 0,02 % ) | 1 M $ | 30/06/2026 |
Postes actifs de Andrew von Eschenbach
| Sociétés | Poste | Début |
|---|---|---|
| BAUSCH + LOMB CORPORATION | Directeur/Membre du Conseil | 01/04/2022 |
Focused Ultrasound Foundation
 Focused Ultrasound Foundation Miscellaneous Commercial ServicesCommercial Services Engages in improving lives of people with serious medical disorders by accelerating the development and adoption of focused ultrasound | Directeur/Membre du Conseil | 09/08/2010 |
Samaritan Health Initiatives, Inc. | Fondateur | 01/01/2010 |
Bausch & Lomb, Inc.
 Bausch & Lomb, Inc. Medical SpecialtiesHealth Technology Manufactures and supplies contact lenses | Directeur/Membre du Conseil | - |
Reagan-udall Foundation
 Reagan-udall Foundation The Reagan-Udall Foundation is a non-profit company dedicated to advancing regulatory science and innovation. The company is based in Washington, DC. The foundation collaborates with various stakeholders to enhance public health and safety through research and development initiatives. Susan C. Winckler has been the CEO of the company since 2020. | Directeur/Membre du Conseil | 01/12/2018 |
Wavebreak Therapeutics Ltd.
 Wavebreak Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops small molecule therapeutics for multiple protein misfolding diseases | Directeur/Membre du Conseil | 01/11/2019 |
Innocrin Pharmaceuticals Holdings LLC
 Innocrin Pharmaceuticals Holdings LLC Medical SpecialtiesHealth Technology Discovers and develops oral inhibitors for the treatment of castration-resistant prostate cancer | Directeur/Membre du Conseil | - |
Innocrin Pharmaceuticals, Inc.
 Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops oral inhibitors for the treatment of castration-resistant prostate cancer | Directeur/Membre du Conseil | - |
Viamet Pharmaceuticals, Inc.
 Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops inhibitors of validated metalloenzymes | Directeur/Membre du Conseil | 20/01/2011 |
| ░░░░░░░░ ░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Anciens postes connus de Andrew von Eschenbach
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░░ ░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░░░░░ ░░░ ░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Andrew von Eschenbach
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
62
Relations au 1er degré
33
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 33 |
|---|---|
Bausch & Lomb, Inc.
Bausch & Lomb, Inc. Medical SpecialtiesHealth Technology Manufactures and supplies contact lenses | Health Technology |
Elan Corp. Plc
 Elan Corp. Plc Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals and drug delivery systems | Health Technology |
Eli Lilly & Co.
 Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
Lineage Cell Therapeutics, Inc.
 Lineage Cell Therapeutics, Inc. BiotechnologyHealth Technology Engages in research and development of therapeutic products for retinal & neurological diseases and disorders and oncology | Health Technology |
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops and commercializes bone health and related therapeutics | Health Technology |
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops inhibitors of validated metalloenzymes | Health Technology |
HistoSonics, Inc.
 HistoSonics, Inc. Medical SpecialtiesHealth Technology Develops non-invasive and sonic beam therapy platform to treat liver tumor | Health Technology |
Viamet Pharmaceuticals Corp.
 Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Develops therapeutic drugs using proprietary metalloenzyme medicinal chemistry | Health Technology |
Asterias Biotherapeutics, Inc.
 Asterias Biotherapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops and commercializes regenerative medicine for neurology and oncology applications | Health Technology |
Innocrin Pharmaceuticals Holdings LLC
Innocrin Pharmaceuticals Holdings LLC Medical SpecialtiesHealth Technology Discovers and develops oral inhibitors for the treatment of castration-resistant prostate cancer | Health Technology |
The University of Texas at Austin
 The University of Texas at Austin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
St. Joseph's University
 St. Joseph's University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
National Cancer Institute
 National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous Conducts research projects & awards grants for cancer research | Miscellaneous |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment Engages in the improvement of health and saving lives | Government |
The University of Texas M.D. Anderson Cancer Center
 The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services Provides cancer patient care, research and prevention for cancer | Consumer Services |
US Food & Drug Administration
 US Food & Drug Administration General GovernmentGovernment Operates agencies to protect health and human services | Government |
Banyan Biomarkers, Inc.
 Banyan Biomarkers, Inc. Medical/Nursing ServicesHealth Services Engages in developing blood test to diagnose traumatic brain injury | Health Services |
National Comprehensive Cancer Network, Inc.
 National Comprehensive Cancer Network, Inc. Miscellaneous Commercial ServicesCommercial Services Provides research and development services to fight against cancer | Commercial Services |
Manhattan Institute For Policy Research, Inc.
 Manhattan Institute For Policy Research, Inc. Miscellaneous Commercial ServicesCommercial Services Develops and disseminate new ideas that foster greater economic choice and individual responsibility | Commercial Services |
Focused Ultrasound Foundation
Focused Ultrasound Foundation Miscellaneous Commercial ServicesCommercial Services Engages in improving lives of people with serious medical disorders by accelerating the development and adoption of focused ultrasound | Commercial Services |
Bausch Health Cos., Inc.
 Bausch Health Cos., Inc. Pharmaceuticals: OtherHealth Technology Manufactures and markets pharmaceutical products | Health Technology |
Reagan-udall Foundation
Reagan-udall Foundation The Reagan-Udall Foundation is a non-profit company dedicated to advancing regulatory science and innovation. The company is based in Washington, DC. The foundation collaborates with various stakeholders to enhance public health and safety through research and development initiatives. Susan C. Winckler has been the CEO of the company since 2020. | |
OncoCyte Corp.
 OncoCyte Corp. BiotechnologyHealth Technology Focuses on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer | Health Technology |
National Comprehensive Cancer Network Foundation | |
Georgetown University School of Medicine
 Georgetown University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Samaritan Health Initiatives, Inc. | |
Innocrin Pharmaceuticals, Inc.
Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops oral inhibitors for the treatment of castration-resistant prostate cancer | Health Technology |
Cypher Genomics, Inc.
 Cypher Genomics, Inc. Information Technology ServicesTechnology Services Provides automated human genome interpretation software solutions | Technology Services |
Wavebreak Therapeutics Ltd.
Wavebreak Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops small molecule therapeutics for multiple protein misfolding diseases | Health Technology |
Celularity, Inc. (United States)
 Celularity, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company which produces allogeneic cells and tissues from postpartum placenta | Commercial Services |
Bausch + Lomb Corp.
 Bausch + Lomb Corp. Medical SpecialtiesHealth Technology Manufactures and sells eye care products | Health Technology |
Celularity, Inc.
 Celularity, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage biotechnology company that discovers cancer sub-types and therapeutic options for cancer patients | Commercial Services |
TriSalus Life Sciences, Inc.
 TriSalus Life Sciences, Inc. Medical SpecialtiesHealth Technology Engages in research, development and sales of innovative drug delivery technology & immune-oncology therapeutics | Health Technology |
